Loading
A phase 3 trial of Trastuzumab pamirtecan run by DualityBio Inc. in her2-positive breast cancer, active.
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer is a phase 3 interventional study registered as NCT06265428 by DualityBio Inc., with 228 participants enrolled, started 2024-01-29. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab pamirtecan, Duality Biotherapeutics, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab pamirtecan, Duality Biotherapeutics, Antibody-drug conjugate (ADC).
Shares Trastuzumab pamirtecan, Duality Biotherapeutics, Antibody-drug conjugate (ADC).
Shares Trastuzumab pamirtecan, Antibody-drug conjugate (ADC).
Shares Duality Biotherapeutics, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/